Prime Medicine (NYSE:PRME) & Invizyne Technologies (NASDAQ:IZTC) Head to Head Review

Prime Medicine (NYSE:PRME) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Earnings & Valuation

This table compares Prime Medicine and Invizyne Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.96 million	162.49	-$198.13 million	($1.56)	-3.84
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Invizyne Technologies has lower revenue, but higher earnings than Prime Medicine.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Prime Medicine and Invizyne Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	3	4	1	2.75
Invizyne Technologies	0	0	0	0	0.00

Prime Medicine currently has a consensus target price of $8.92, indicating a potential upside of 48.86%. Given Prime Medicine’s stronger consensus rating and higher possible upside, equities analysts plainly believe Prime Medicine is more favorable than Invizyne Technologies.

Profitability

This table compares Prime Medicine and Invizyne Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-107.87%	-74.97%
Invizyne Technologies	N/A	N/A	N/A

Insider and Institutional Ownership

70.4% of Prime Medicine shares are held by institutional investors. 22.7% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Prime Medicine beats Invizyne Technologies on 7 of the 9 factors compared between the two stocks.

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

About Invizyne Technologies

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.